Tamoxifen: a receptor blocker that leaves the hormone alone

An aromatase inhibitor lowers the hormone. Tamoxifen leaves the hormone where it is and blocks the receptor in the tissue that matters. Those are different interventions with different consequences, and conflating them is the most common error made about it.

Selective, and what the selectivity means

Established clinical use Tamoxifen is a selective oestrogen receptor modulator: it antagonises the receptor in some tissues and acts as an agonist in others. In breast tissue it is an antagonist, which is the basis for both its oncology approval and its off-label use for gynaecomastia. In bone and in the liver it behaves more like an agonist, which is why it does not carry the bone-density concern that oestrogen suppression does and why it affects lipids the way it does.

That tissue selectivity is the whole reason to prefer it over an aromatase inhibitor for a breast-tissue problem. An aromatase inhibitor lowers estradiol everywhere — including the bone, the brain and the vasculature where a man needs it — to fix a problem in one tissue. Tamoxifen blocks the receptor where the problem is and leaves circulating estradiol intact. The anastrozole page covers what over-suppression costs.

Its half-life is long — the app models about six days, and the active metabolites run longer still — so it accumulates over weeks and clears over weeks. An effect assessed at a fortnight is being assessed before the level has settled.

What it does for gynaecomastia, and when

Off-label or community practice Gynaecomastia is glandular proliferation, and the window in which it responds to anything pharmacological is early. In the proliferative phase, while the tissue is tender and recently changed, receptor blockade can reduce or reverse it. Once the tissue has become fibrotic — typically after about a year — no drug reliably removes it, and surgery is the only thing that does. That timeline is the single most practically useful fact on this page.

It is also why the honest answer to "will this fix it" is a question about how long it has been there. Someone with tender, recently developed tissue is in a different situation from someone with a firm, painless, long-standing lump, and only the first has a pharmacological option worth trying.

Why there is no dosing table on this page

You will notice this page carries no reproduced dosing rows. That is deliberate and automatic: the two rows the app holds for tamoxifen are a post-cycle recovery protocol and a during-cycle prevention schedule, and the generator strips rows framed that way before a page is built. Every compound page here is filtered the same way; tamoxifen is simply the one entry where nothing survives it.

What is left to say is the approved pharmacology, which is what this page covers. The amounts used in the oncology indication are published in the labelling and are a prescribing matter, not a page’s.

The risk worth naming is thromboembolism. Tamoxifen raises the risk of venous thromboembolic events, which is established in the oncology trial data, and it is the reason a personal or family history of clotting matters here more than it does with most things in this reference. Visual disturbance is the other class effect with a conventional instruction attached: blurring or persistent after-images are a reason to stop and contact the prescriber rather than to continue and watch. Anything on the drawbacks list below belongs in the same conversation.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Tamoxifen, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Total testosterone
• LH and FSH

Drawbacks and risks the app records

From the app’s own entry. The clot item is the one that changes who should be taking this at all rather than how much.

• Mood effects reported in some users
• Visual disturbances (rare, reversible)
• Blood clot risk at high doses
• Not for long-term use
• Hot flashes possible

Interaction rules that name Tamoxifen

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Tamoxifen or an aromatase inhibitor for gynaecomastia?

They work differently. Tamoxifen blocks the receptor in the tissue with the problem and leaves circulating estradiol alone; an aromatase inhibitor lowers estradiol everywhere. For a breast-tissue problem the first is the more targeted intervention. Which is appropriate is a prescribing decision.

Does it lower estradiol?

No. It does not reduce production at all — it occupies the receptor. Someone expecting the estradiol number on their panel to fall will be confused by a result that has not moved, and the unchanged number is not evidence the drug is not working.

How long does gynaecomastia stay treatable?

Roughly the first year, while the tissue is still proliferative and usually tender. Once it fibroses, no drug reliably reverses it. That makes the timing of the conversation more important than the choice of drug.

Why does this page show no dosing rows?

Because both rows the app holds for tamoxifen are post-cycle or during-cycle protocols, and the generator strips those from every compound page before building it. Tamoxifen is the one entry where that leaves nothing.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.